Ironwood Pharmaceuticals (IRWD) Q4 2025 earnings summary

Executive summary

• Achieved full year 2025 guidance with $865M in LINZESS U.S. net sales, driven by 11% demand growth and 8% new-to-brand volume growth year-over-year.

• LINZESS received FDA approval for IBS-C in patients aged 7–17, expanding its clinical profile.

• Advanced apraglutide program, aligning with FDA on Phase III STARS-2 trial design, with site activation expected in Q2 2026.

• Ended 2025 with $215M in cash and cash equivalents, supporting ongoing operations, 2026 growth, and deleveraging.

• 2026 priorities: maximize LINZESS, advance apraglutide, maintain disciplined expense management, and reduce debt.

Financial highlights

• LINZESS net sales: $163M in Q4 2025 (down 27% YoY), $865M for full year (down 6% YoY), with net price erosion offset by 11–13% prescription demand growth.

• Total revenue: $296M; GAAP net income: $24M; Adjusted EBITDA: $138M.

• Operating expenses reduced by $61M YoY, generating $127M in cash flows from operations.

• Commercial margin on LINZESS sales was 66% for FY25.

• Ended 2025 with $215M in cash and cash equivalents.

Outlook and guidance

• 2026 LINZESS U.S. net sales expected between $1.125B–$1.175B, a >30% YoY increase, driven by improved net price and low single-digit demand growth.

• Total revenue guidance: $450M–$475M; Adjusted EBITDA: >$300M.

• Plan to reduce total debt to ~$300M by year-end 2026, less than 1x 2026 Adjusted EBITDA.

• Strong LINZESS cash flows expected to enable continued deleveraging and fund long-term growth.

• No material expenses from business development activities assumed in FY26 guidance.